<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04886726</url>
  </required_header>
  <id_info>
    <org_study_id>14916</org_study_id>
    <nct_id>NCT04886726</nct_id>
  </id_info>
  <brief_title>PTCY Plus uhCG/EGF for Graft Versus Host Disease Prophylaxis</brief_title>
  <official_title>Post-transplant Cyclophosphamide and Urinary-derived Human Chorionic Gonadotropin and Epidermal Growth Factor (uhCG/EGF) as Graft Versus Host Disease Prophylaxis for Mismatched Unrelated Donor Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henry Ford Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Henry Ford Health System</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      So this a Phase I study with primary objective to determine the feasibility and safety of&#xD;
      combining post-transplant cyclophosphamide and urinary-derived human chorionic gonadotropin&#xD;
      and epidermal growth factor (uhCG/EGF) as graft versus host disease prophylaxis in stem cell&#xD;
      transplant with MMUDs Secondary objectives are to determine the incidence acute and chronic&#xD;
      GVHD, progression-free survival , and overall survival&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2025</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD</measure>
    <time_frame>day+30 post SCT</time_frame>
    <description>The maximum tolerated dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of dose limiting toxicity (DLTs)</measure>
    <time_frame>day+30 post SCT</time_frame>
    <description>The overall incidence and severity of DLTs for uhCG/EGF</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>acute GVHD</measure>
    <time_frame>till day +100 post SCT</time_frame>
    <description>Cumulative incidence of acute GVHD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic GVHD</measure>
    <time_frame>one year post SCT</time_frame>
    <description>Cumulative incidence of chronic GVHD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>one year post SCT</time_frame>
    <description>Death from any cause will be considered an event. Surviving patients will be censored at the time of last follow up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>one year</time_frame>
    <description>Survival following allogeneic SCT without relapse or progression. Relapse or progression of disease, or death are considered events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Graft Versus Host Disease</condition>
  <arm_group>
    <arm_group_label>PTCY and uhCG/EGF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PTCY for 2 doses on day +3 and +4 after stem cell transplant followed by uhCG/EGF subcutaneously on day +7, +9 and +11 post stem cell transplant</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>uhCG/EGF</intervention_name>
    <description>PTCY for 2 doses on day +3 and +4 after stem cell transplant followed by uhCG/EGF subcutaneously on day +7, +9 and +11 post stem cell transplant</description>
    <arm_group_label>PTCY and uhCG/EGF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with hematologic malignancy who have the indication for Allogeneic SCT and&#xD;
             have no MRD or MUD.&#xD;
&#xD;
          2. Age 18-70 years old&#xD;
&#xD;
          3. Performance score of at least 80% by Karnofsky&#xD;
&#xD;
          4. Adequate kidney and liver function as demonstrated by:&#xD;
&#xD;
               1. Creatinine clearance should be &gt;60 ml/min&#xD;
&#xD;
               2. Total Bilirubin &lt;1.5, ALT/AST/Alk Phos &lt; 2.5 x normal. No evidence of chronic&#xD;
                  active hepatitis or cirrhosis.&#xD;
&#xD;
          5. Negative Beta HCG test in a woman with childbearing potential, defined as not&#xD;
             post-menopausal for 12 months or no previous surgical sterilization. Women of&#xD;
             childbearing potential must be willing to use an effective contraceptive measure while&#xD;
             on study.&#xD;
&#xD;
          6. Patient or patient's legal representative, parent(s) or guardian able to sign informed&#xD;
             consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Positive for HIV, HBsAg, HCV or other viral hepatitis or cirrhosis from any cause&#xD;
&#xD;
          2. Active or prior CNS leukemia, unless in complete remission for at least 2 months.&#xD;
&#xD;
          3. History of serious chronic mental disorder or drug-abuse accompanied by documented&#xD;
             problems of compliance with therapeutic programs.&#xD;
&#xD;
          4. Uncontrolled infection&#xD;
&#xD;
          5. Donor specific antibodies&#xD;
&#xD;
          6. Ejection fraction &lt;40% or history of heart failure or cardiovascular disease&#xD;
&#xD;
          7. history thrombosis or current thrombosis, family history of thrombosis, severe&#xD;
             obesity, or thrombophilia.&#xD;
&#xD;
          8. Previous history hormone responsive cancer&#xD;
&#xD;
          9. history of seizure&#xD;
&#xD;
         10. history of migraine or severe headache&#xD;
&#xD;
         11. history of asthma&#xD;
&#xD;
         12. history of uterine fibroid&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>shatha farhan</last_name>
    <phone>3137133910</phone>
    <email>sfarhan1@hfhs.org</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 5, 2021</study_first_submitted>
  <study_first_submitted_qc>May 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2021</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Henry Ford Health System</investigator_affiliation>
    <investigator_full_name>Shatha Farhan</investigator_full_name>
    <investigator_title>Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

